Eli Lilly’s donanemab faces a setback as EMA’s CHMP issues a negative opinion. Analysts expect Lilly to appeal, citing past reversals in similar cases.
Latest Ratings for LLY
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | Morgan Stanley | Maintains | Overweight | |
| Feb 2022 | Mizuho | Maintains | Buy | |
| Jan 2022 | Morgan Stanley | Maintains | Overweight |
